BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Roberts LT, Issa PP, Sinnathamby ES, Granier M, Mayeux H, Eubanks TN, Malone K, Ahmadzadeh S, Cornett EM, Shekoohi S, Kaye AD. Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice. Life (Basel) 2022;12. [PMID: 36556402 DOI: 10.3390/life12122038] [Reference Citation Analysis]
2 Nikbazm R, Rahimi Z, Moradi Y, Alipour M, Shidfar F. The effect of cranberry supplementation on Helicobacter pylori eradication in H. pylori positive subjects: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2022;128:1090-9. [PMID: 34670631 DOI: 10.1017/S0007114521004256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhao Q, Wang W, Zhou S, Su J, Sun H, Zhai J, Hu Y. Jinghua Weikang capsule for helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Front Pharmacol 2022;13:959184. [DOI: 10.3389/fphar.2022.959184] [Reference Citation Analysis]
4 Salinas Ibáñez ÁG, Origone AL, Liggieri CS, Barberis SE, Vega AE. Asclepain cI, a proteolytic enzyme from Asclepias curassavica L., a south American plant, against Helicobacter pylori. Front Microbiol 2022;13:961958. [DOI: 10.3389/fmicb.2022.961958] [Reference Citation Analysis]
5 Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther 2022;56:436-49. [PMID: 35665947 DOI: 10.1111/apt.17070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Shen H, Chen Y, Li X, Yan J, Zhao J, Kong D, Shi Y, Li Z, Wang J, Shao N, Wang Z. Impact of Helicobacter pylori Infection and Outcome of Anti-Helicobacter pylori Therapy in Patients with Reflux Laryngopharyngitis. Evid Based Complement Alternat Med 2022;2022:8266321. [PMID: 35836834 DOI: 10.1155/2022/8266321] [Reference Citation Analysis]
7 Pop R, Tăbăran A, Ungur AP, Negoescu A, Cătoi C. Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles. Pharmaceutics 2022;14:1463. [DOI: 10.3390/pharmaceutics14071463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Saha K, Sarkar D, Khan U, Karmakar BC, Paul S, Mukhopadhyay AK, Dutta S, Bhattacharya S. Capsaicin Inhibits Inflammation and Gastric Damage during H pylori Infection by Targeting NF-kB–miRNA Axis. Pathogens 2022;11:641. [DOI: 10.3390/pathogens11060641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Antoniciello F, Roncarati D, Zannoni A, Chiti E, Scarlato V, Chiappori F. Targeting the Essential Transcription Factor HP1043 of Helicobacter pylori: A Drug Repositioning Study. Front Mol Biosci 2022;9:887564. [DOI: 10.3389/fmolb.2022.887564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Reiprich A, Skalden L, Raab A, Bolotina N, Lang C. Lactobacillus crispatus DSM25988 as novel bioactive agent to co-aggregate Streptococcus pyogenes and to exclude it by binding to human cells. Benef Microbes 2022;:1-12. [PMID: 35144524 DOI: 10.3920/BM2021.0103] [Reference Citation Analysis]
11 Salinas Ibáñez ÁG, Vallés D, Adaro M, Barberis S, Vega AE. Antimicrobial Effect of a Proteolytic Enzyme From the Fruits of Solanum granuloso-leprosum (Dunal) Against Helicobacter pylori. Front Nutr 2021;8:699955. [PMID: 34977105 DOI: 10.3389/fnut.2021.699955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mulay V, Satav D, Fernandez A, Pisalwar P, Ahmed S. Development of Probiotics for Helicobacter pylori Infection Management. Alternatives to Antibiotics 2022. [DOI: 10.1007/978-981-19-1854-4_20] [Reference Citation Analysis]
13 Inose R, Muraki Y, Kamimoto Y, Kusama Y, Koizumi R, Yamasaki D, Ishikane M, Tanabe M, Ohmagari N. The intended purpose and regional patterns of use of antibiotics for managing Clostridioides (Clostridium) difficile infections: An analysis of the National Database of Health Insurance Claims and Specific Health Checkups data of Japan. J Infect Chemother 2021:S1341-321X(21)00340-8. [PMID: 34916136 DOI: 10.1016/j.jiac.2021.12.004] [Reference Citation Analysis]
14 Wylie MR, Windham IH, Blum FC, Wu H, Merrell DS. In vitro antibacterial activity of nimbolide against Helicobacter pylori. J Ethnopharmacol 2021;:114828. [PMID: 34763046 DOI: 10.1016/j.jep.2021.114828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Khan S, Sharaf M, Ahmed I, Khan TU, Shabana S, Arif M, Kazmi SSUH, Liu C. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34658307 DOI: 10.1080/14787210.2022.1990041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Choi YI, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Seo JY, Park DK. Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients. World J Gastroenterol 2021; 27(31): 5247-5258 [PMID: 34497448 DOI: 10.3748/wjg.v27.i31.5247] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Gong M, Han Y, Wang X, Tao H, Meng F, Hou B, Sun BB, Wang G. Effect of Temperature on Metronidazole Resistance in Helicobacter pylori. Front Microbiol 2021;12:681911. [PMID: 34093508 DOI: 10.3389/fmicb.2021.681911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ozturk T, Sengul D, Sengul I. Helicobacter pylori and association between its positivity and anatomotopographic settlement in the stomach with the host age range. Ann Afr Med 2021;20:1-8. [PMID: 33727504 DOI: 10.4103/aam.aam_69_19] [Reference Citation Analysis]
19 Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 DOI: 10.3390/antibiotics10020214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Palencia M, Lerma TA, Garcés V, Mora MA, Martínez JM, Palencia SL. Polymeric drug carriers against Helicobacter pylori. Eco-friendly Functional Polymers 2021. [DOI: 10.1016/b978-0-12-821842-6.00006-3] [Reference Citation Analysis]
21 Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, Gartner F, Touati E, Gomes J, Costa P, Martins MCL, Gonçalves IC. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta Biomater 2020;114:206-20. [PMID: 32622054 DOI: 10.1016/j.actbio.2020.06.035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
22 Amadei SS, Notario V. A Significant Question in Cancer Risk and Therapy: Are Antibiotics Positive or Negative Effectors? Current Answers and Possible Alternatives. Antibiotics (Basel) 2020;9:E580. [PMID: 32899961 DOI: 10.3390/antibiotics9090580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
24 Zeeb M, Kerrinnes T, Cicin-Sain L, Guzman CA, Puppe W, Schulz TF, Peters A, Berger K, Castell S, Karch A. Seropositivity for pathogens associated with chronic infections is a risk factor for all-cause mortality in the elderly: findings from the Memory and Morbidity in Augsburg Elderly (MEMO) Study. Geroscience 2020;42:1365-76. [PMID: 32648237 DOI: 10.1007/s11357-020-00216-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Palacios-gorba C, Pina R, Tortajada-girbés M, Jiménez-belenguer A, Siguemoto É, Ferrús MA, Rodrigo D, Pina-pérez MC. Caenorhabditis elegans as an in vivo model to assess fucoidan bioactivity preventing Helicobacter pylori infection. Food Funct 2020;11:4525-34. [DOI: 10.1039/d0fo00768d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
26 Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: Current status and rational treatment options. North Clin Istanb 2020;7:87-94. [PMID: 32232212 DOI: 10.14744/nci.2019.62558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
27 Bruce MG, Bruden D, Newbrough D, Hurlburt DA, Hennessy TW, Morris JM, Reasonover AL, Sacco F, Mcmahon BJ. The relationship between previous antimicrobial use, antimicrobial resistance and treatment outcome among Alaskans treated forHelicobacter pyloriinfection. GastroHep 2019. [DOI: 10.1002/ygh2.352] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Amin M, Shayesteh AA, Serajian A, Goodarzi H. Assessment of Metronidazole and Clarithromycin Resistance Among Helicobacter pylori Isolates of Ahvaz (Southwest of Iran) During 2015 - 2016 by Phenotypic and Molecular Methods. Jundishapur J Microbiol 2019;In Press. [DOI: 10.5812/jjm.80156] [Reference Citation Analysis]
29 Haverich A, Boyle EC. Atherosclerosis Risk Factors. Atherosclerosis Pathogenesis and Microvascular Dysfunction 2019. [DOI: 10.1007/978-3-030-20245-3_2] [Reference Citation Analysis]
30 Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018;155:1372-1382.e17. [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007] [Cited by in Crossref: 456] [Cited by in F6Publishing: 460] [Article Influence: 91.2] [Reference Citation Analysis]
31 Hathroubi S, Zerebinski J, Ottemann KM. Helicobacter pylori Biofilm Involves a Multigene Stress-Biased Response, Including a Structural Role for Flagella. mBio. 2018;9:e01973-18. [PMID: 30377283 DOI: 10.1128/mbio.01973-18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
32 Hathroubi S, Zerebinski J, Ottemann KM. The Helicobacter pylori biofilm involves a multi-gene stress-biased response including a structural role for flagella.. [DOI: 10.1101/412239] [Reference Citation Analysis]
33 Al-Eraky DM, Helmy OM, Ragab YM, Abdul-Khalek Z, El-Seidi EA, Ramadan MA. Prevalence of CagA and antimicrobial sensitivity of H. pylori isolates of patients with gastric cancer in Egypt. Infect Agent Cancer. 2018;13:24. [PMID: 30026792 DOI: 10.1186/s13027-018-0198-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
34 Chung JW, Kim SY, Park HJ, Chung CS, Lee HW, Lee SM, Kim I, Pak JH, Lee GH, Jeong JY. In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains. Gut Liver. 2017;11:648-654. [PMID: 28750485 DOI: 10.5009/gnl16503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
35 Chaudhry A. Pharmacist guidelines and considerations for treating H. pylori. JAPLR 2018;7. [DOI: 10.15406/japlr.2018.07.00222] [Reference Citation Analysis]
36 Tarhini M, Fayyad-kazan M, Fayyad-kazan H, Mokbel M, Nasreddine M, Badran B, Kchour G. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. Microbial Pathogenesis 2018;117:23-6. [DOI: 10.1016/j.micpath.2018.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
37 Poursina F, Fagri J, Mirzaei N, Safaei HG. Overexpression of spoT gene in coccoid forms of clinical Helicobacter pylori isolates. Folia Microbiol (Praha) 2018;63:459-65. [PMID: 29327293 DOI: 10.1007/s12223-017-0557-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
38 Serajian A. PCR-RFLP Detection of Point Mutations in 23sr RNA Gene Responsible for Clarithromycin Resistance in Helicobacter pylori Isolates of Ahvaz, Iran. IJMBOA 2017;2. [DOI: 10.15406/ijmboa.2017.02.00038] [Reference Citation Analysis]
39 Sadra A, Kweon HS, Huh SO, Cho J. Gastroprotective and gastric motility benefits of AD-lico/Healthy Gut™ Glycyrrhiza inflata extract. Anim Cells Syst (Seoul) 2017;21:255-62. [PMID: 30460076 DOI: 10.1080/19768354.2017.1357660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 2017;22. [PMID: 28098408 DOI: 10.1111/hel.12374] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
41 Fahimi F, Tohidkia MR, Fouladi M, Aghabeygi R, Samadi N, Omidi Y. Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy. Bioimpacts 2017;7:59-71. [PMID: 28546954 DOI: 10.15171/bi.2017.08] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
42 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
43 Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
44 Czyrski A. Analytical Methods for Determining Third and Fourth Generation Fluoroquinolones: A Review. Chromatographia 2017;80:181-200. [PMID: 28216694 DOI: 10.1007/s10337-016-3224-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
45 Modak JK, Liu YC, Supuran CT, Roujeinikova A. Structure-Activity Relationship for Sulfonamide Inhibition of Helicobacter pylori α-Carbonic Anhydrase. J Med Chem 2016;59:11098-109. [PMID: 28002963 DOI: 10.1021/acs.jmedchem.6b01333] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
46 Liu AR, Du YQ. Current status of Helicobacter pylori infection and evolution of treatment strategy in China. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4396-4403 [DOI: 10.11569/wcjd.v24.i32.4396] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, Ishii M, Kamada T, Haruma K, Graham DY. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci 2016;61:3215-20. [PMID: 27659671 DOI: 10.1007/s10620-016-4305-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
48 Goli YD, Moniri R. Efficacy of probiotics as an adjuvant agent in eradication of Helicobacter pylori infection and associated side effects. Beneficial Microbes 2016;7:519-27. [DOI: 10.3920/bm2015.0130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res 2016;5:F1000 Faculty Rev-1747. [PMID: 30023042 DOI: 10.12688/f1000research.8598.1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
50 Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol 2016;111:949-56. [PMID: 27185079 DOI: 10.1038/ajg.2016.182] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 9.6] [Reference Citation Analysis]
51 Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016;65:870-8. [PMID: 26848181 DOI: 10.1136/gutjnl-2015-311019] [Cited by in Crossref: 142] [Cited by in F6Publishing: 127] [Article Influence: 20.3] [Reference Citation Analysis]
52 Talebi Bezmin Abadi A. Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol 2016; 22(11): 3150-3157 [PMID: 27003991 DOI: 10.3748/wjg.v22.i11.3150] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]